Metabolomics: A global biochemical approach to the discovery of biomarkers for psychiatric disorders

Biomarkers for Psychiatric Disorders

Volumn , Issue , 2009, Pages 129-162

  Kaddurah Daouk, Rima ^a   Soares, Jair C ^b   Quinones, Marlon P ^b  

^a DUKE UNIVERSITY MEDICAL CENTER   (United States)

^b NONE

Author keywords

[No Author keywords available]

Indexed keywords

EID: 84900259275     PISSN: None     EISSN: None     Source Type: Book    
DOI: 10.1007/978-0-387-79251-4_6     Document Type: Chapter

References (178)

1. Appleton KM, Hayward RC, Gunnell D, et al.: Effects of n-3 long-chain polyunsaturated fatty acids on depressed mood: Systematic review of published trials. Am J Clin Nutr 84: 1308-1316, 2006.
2. Audenaert K, Peremans K, Goethals I, et al.: Functional imaging, serotonin and the suicidal brain. Acta Neurol Belg 106:125-131, 2006.
3. Bakhtiar R: Biomarkers in drug discovery and development. J Pharmacol Toxicol Meth 57:85-91, 2008.
4. Bell C, Abrams J, Nutt D: Tryptophan depletion and its implications for psychiatry. Br J Psychiatr 178:399-405, 2001.
5. Berger GE, Wood SJ, Pantelis C, et al.: Implications of lipid biology for the pathogenesis of schizophrenia. Aust New Zeal J Psychiatr 36:355-366, 2002.
6. Berrettini WH, Nurnberger JI, Jr., Scheinin M, et al.: Cerebrospinal fluid and plasma monoamines and their metabolites in euthymic bipolar patients. Biol Psychiatr 20:257-269, 1985.
7. Bhagwagar Z, Wylezinska M, Jezzard P, et al.: Low GABA concentrations in occipital cortex and anterior cingulate cortex in medication-free, recovered depressed patients. Int J Neuropsychopharmacol 1-6, 2007.
8. Biomarkers and surrogate endpoints: Preferred definitions and conceptual framework. Clin Pharmacol Ther 69:89-95, 2001.
9. Birkenhager TK, van den Broek WW, Fekkes D, et al.: Lithium addition in antidepressant-resistant depression: Effects on platelet 5-HT, plasma 5-HT and plasma 5-HIAA concentration. Prog Neuropsychopharmacol Biol Psychiatr 31:1084-1088, 2007.
10. Bogdanov M, Matson WR, Wang L, Matson T, Saunders-Pullman R, Bressman SS, Flint Beal M. Metabolomic profiling to develop blood biomarkers for Parkinson's disease. Brain 131389-96, 2008.
11. Bowers MB, Jr., Mazure CM, Nelson JC, et al.: Lithium in combination with perphenazine: Effect on plasma monoamine metabolites. Biol Psychiatr 32:1102-1107, 1992.
12. Brambilla P, Perez J, Barale F, et al.: GABAergic dysfunction in mood disorders. Mol Psychiatr 8:721-737, 715, 2003.
13. Breier A: Serotonin, schizophrenia and antipsychotic drug action. Schizophr Res 14:187-202, 1995.
14. Brindle JT, Antti H, Holmes E, et al.: Rapid and noninvasive diagnosis of the presence and severity of coronary heart disease using 1H-NMR-based metabonomics. Nat Med 8:1439-1444, 2002.
15. Brindle JT, Nicholson JK, Schofield PM, et al.: Application of chemometrics to 1H NMR spectroscopic data to investigate a relationship between human serum metabolic profiles and hypertension. Analyst 128:32-36, 2003.
16. Brown AS, Gewirtz G, Harkavy-Friedman J, et al.: Effects of clozapine on plasma catecholamines and relation to treatment response in schizophrenia: A within-subject comparison with haloperidol. Neuropsychopharmacology 17:317-325, 1997.
17. Casey DE: Dyslipidemia and atypical antipsychotic drugs. J Clin Psychiatr 65(Suppl. 18):27-35, 2004.
18. Chou JC, Czobor P, Tuma I, et al.: Pretreatment plasma HVA and haloperidol response in acute mania. J Affect Disord 59:55-59, 2000.
19. Coen M, Ruepp SU, Lindon JC, et al.: Integrated application of transcriptomics and metabonomics yields new insight into the toxicity due to paracetamol in the mouse. J Pharm Biomed Anal 35:93-105, 2004.
20. Coppen A: Electrolytes and mental illness. Proc Annu Meet Am Psychopathol Assoc 58:397-409, 1969.
21. Correll CU, Frederickson AM, Kane JM, et al.: Does antipsychotic polypharmacy increase the risk for metabolic syndrome? Schizophr Res 89:91-100, 2007.
22. Crocker IP, Kenny LC, Thornton WA, et al.: Excessive stimulation of poly(ADP-ribosyl)ation contributes to endothelial dysfunction in pre-eclampsia. Br J Pharmacol 144:772-780, 2005.
23. Curzon G. Relationships between plasma, CSF and brain tryptophan J Neural Transm (Suppl 81-92 1979.
24. Curzon G: Influence of plasma tryptophan on brain 5HT synthesis and serotonergic activity. Adv Exp Med Biol 133:207-219, 1981.
25. Dauner M, Bailey JE, U. S: Metabolic flux analysis with a comprehensive isotopomer model in Bacillus subtilis. Biotechnol Bioeng 76:1440156, 2001.
26. Davila R, Zumarraga M, Basterreche N, et al.: Influence of the catechol-O-methyltransferase Val108/158Met polymorphism on the plasma concentration of catecholamine metabolites and on clinical features in type I bipolar disorder-A preliminary report. J Affect Disord 92:277-281, 2006.
27. de Graaf AA, Mahle M, Möllney M, et al.: Determination of full 13C isotopomer distributions for metabolic flux analysis using heteronuclear spin echo difference NMR spectroscopy. J Biotechnol 77:25035, 2000.
28. De Milito A, Titanji K, Zazzi M: Surrogate markers as a guide to evaluate response to antiretroviral therapy. Curr Med Chem 10:349-365, 2003.
29. Deeks JJ, Altman DG: Diagnostic tests 4: Likelihood ratios. BMJ 329:168-169, 2004.
30. Delgado PL, Moreno FA: Role of norepinephrine in depression. J Clin Psychiatr 61(Suppl. 1): 5-12, 2000.
31. Delgado PL: How antidepressants help depression: Mechanisms of action and clinical response. J Clin Psychiatr 65(Suppl. 4):25-30, 2004.
32. Delgado PL: Monoamine depletion studies: Implications for antidepressant discontinuation syndrome. J Clin Psychiatr 67 (Suppl. 4):22-26, 2006.
33. Denkert C, Budczies J, Kind T, et al.: Mass spectrometry-based metabolic profiling reveals different metabolite patterns in invasive ovarian carcinomas and ovarian borderline tumors. Cancer Res 66:10795-10804, 2006.
34. Dunne VG, Bhattachayya S, Besser M, et al.: Metabolites from cerebrospinal fluid in aneurysmal subarachnoid haemorrhage correlate with vasospasm and clinical outcome: A pattern-recognition 1H NMR study. NMR Biomed 18:24-33, 2005.
35. Ebuehi OA, Bishop SA, Fanmuyiwa OO, et al.: Biogenic amines metabolism and blood chemistry of psychiatric patients. Afr J Med Med Sci 30:269-273, 2001.
36. Ellis PM, Mellsop GW, Beeston R, et al.: Platelet tritiated imipramine binding in patients suffering from mania. J Affect Disord 22:105-110, 1991.
37. Ellison G: Stimulant-induced psychosis, the dopamine theory of schizophrenia, and the habenula. Brain Res Brain Res Rev 19:223-239, 1994.
38. Fan C, Oh DS, Wessels L, et al.: Concordance among gene-expression-based predictors for breast cancer. N Engl J Med 355:560-569, 2006.
39. Fan TW-M, Lane AN: Structure-based profiling of metabolites and isotopomers by NMR. Prog NMR Spectrosc, in press.
40. Fan X, Bai J, Shen P: Diagnosis of breast cancer using HPLC metabonomics fingerprints coupled with computational methods. Conf Proc IEEE Eng Med Biol Soc 6:6081-6084, 2005.
41. Fortunati F, Mazure C, Preda A, et al.: Plasma catecholamine metabolites in antidepressantexacerbated mania and psychosis. J Affect Disord 68:331-334, 2002.
42. Frank R, Hargreaves R: Clinical biomarkers in drug discovery and development. Nat Rev Drug Discov 2:566-580, 2003.
43. Freeman MP, Hibbeln JR, Wisner KL, et al.: Omega-3 fatty acids: Evidence basis for treatment and future research in psychiatry. J Clin Psychiatr 67 1954-1967 2006
44. Frye MA, Tsai GE, Huggins T, et al.: Low cerebrospinal fluid glutamate and glycine in refractory affective disorder. Biol Psychiatr 61:162-166, 2007.
45. Garcia-Portilla MP, Saiz PA, Benabarre A, et al.: The prevalence of metabolic syndrome in patients with bipolar disorder. J Affect Disord 106:197-201, 2008.
46. Garfinkel PE, Warsh JJ, Stancer HC: Depression: New evidence in support of biological differentiation. Am J Psychiatr 136:535-539, 1979.
47. German JB, Gillies LA, Smilowitz JT, et al.: Lipidomics and lipid profiling in metabolomics. Curr Opin Lipidol 18:66-71, 2007.
48. Gerner RH, Fairbanks L, Anderson GM, et al.: CSF neurochemistry in depressed, manic, and schizophrenic patients compared with that of normal controls. Am J Psychiatr 141: 1533-1540, 1984.
49. Goodwin FK, Sack RL: Central dopamine function in affective illness: Evidence from precursors, enzyme inhibitors, and studies of central dopamine turnover. Adv Biochem Psychopharmacol 12:261-279, 1974.
50. Goodwin FK, Jamison KR, Ghaemi SN: Manic-depressive illness: Bipolar disorders and recurrent depression, 2nd Edition. New York: Oxford University Press, 2007.
51. Greenspan K, Schildkraut JJ, Gordon EK, et al.: Catecholamine metabolism in affective disorders. 3. MHPG and other catecholamine metabolites in patients treated with lithium carbonate. J Psychiatr Res 7:171-183, 1970.
52. Grossman F, Potter WZ: Catecholamines in depression: A cumulative study of urinary norepinephrine and its major metabolites in unipolar and bipolar depressed patients versus healthy volunteers at the NIMH. Psychiatr Res 87:21-27, 1999.
53. Hall JA, Brown R, Paul J: An exploration into study design for biomarker identification: Issues and recommendations. Cancer Genomics Proteomics 4:111-119, 2007.
54. Han X, Holtzman DM, McKeel DW, Jr., et al.: Substantial sulfatide deficiency and ceramide elevation in very early Alzheimer's disease: Potential role in disease pathogenesis. J Neurochem 82:809-818, 2002.
55. Harrigan G, Goodacre R: Metabolic profiling: Its role in biomarker discovery and gene function analysis. Boston: Kluwer, 2003.
56. Hasler G, van der Veen JW, Tumonis T, et al.: Reduced prefrontal glutamate/glutamine and gamma-Aminobutyric acid levels in major depression determined using proton magnetic resonance spectroscopy. Arch Gen Psychiatr 64:193-200, 2007.
57. Heritch AJ: Evidence for reduced and dysregulated turnover of dopamine in schizophrenia. Schizophr Bull 16:605-615, 1990.
58. Hoekstra R, Fekkes D, Loonen AJ, et al.: Bipolar mania and plasma amino acids: Increased levels of glycine. Eur Neuropsychopharmacol 16:71-77, 2006.
59. Holmes E, Tsang TM, Huang JT, et al.: Metabolic profiling of CSF: Evidence that early intervention may impact on disease progression and outcome in schizophrenia. PLoS Med 3:e327, 2006.
60. Horrobin DF: The roles of prostaglandins and prolactin in depression, mania and schizophrenia. Postgrad Med J 53 (Suppl. 4):160-165, 1977.
61. Horrobin DF, Manku MS, Hillman H, et al.: Fatty acid levels in the brains of schizophrenics and normal controls. Biol Psychiatr 30:795-805, 1991.
62. Horrobin DF: Schizophrenia as a membrane lipid disorder which is expressed throughout the body. Prostaglandins Leukot Essent Fatty Acids 55:3-7, 1996.
63. Horrobin DF: The membrane phospholipid hypothesis as a biochemical basis for the neurodevelopmental concept of schizophrenia. Schizophr Res 30:193-208, 1998.
64. Janowsky DS, el-Yousef MK, Davis JM, et al.: Cholinergic reversal of manic symptoms. Lancet 1:1236-1237, 1972.
65. Janowsky DS, el-Yousef MK, Davis JM, et al.: A cholinergic-Adrenergic hypothesis of mania and depression. Lancet 2:632-635, 1972.
66. Joyce PR, Fergusson DM, Woollard G, et al.: Urinary catecholamines and plasma hormones predict mood state in rapid cycling bipolar affective disorder. J Affect Disord 33:233-243, 1995.
67. Kaddurah-Daouk R: Metabolic profiling of patients with schizophrenia. PLoS Med 3:e363, 2006.
68. Kaddurah-Daouk R, McEvoy J, Baillie RA, et al.: Metabolomic mapping of atypical antipsychotic effects in schizophrenia. Mol Psychiatr 12:934-945, 2007.
69. Kaddurah-Daouk R, Kristal BS, Weinshilboum RM: Metabolomics: A global biochemical approach to drug response and disease. Annu Rev Pharmacol Toxicol 48:653-683, 2008.
70. Kasa K, Otsuki S, Yamamoto M, et al.: Cerebrospinal fluid gamma-Aminobutyric acid and homovanillic acid in depressive disorders. Biol Psychiatr 17:877-883, 1982.
71. Kell DB: Metabolomics and systems biology: Making sense of the soup. Curr Opin Micro 7:296-307, 2004.
72. Kelley ME, Yao JK, van Kammen DP: Plasma catecholamine metabolites as markers for psychosis and antipsychotic response in schizophrenia. Neuropsychopharmacology 20:603-611, 1999.
73. Kessler RC, Berglund P, Demler O, et al.: The epidemiology of major depressive disorder: Results from the National Comorbidity Survey Replication (NCS-R). JAMA 289:3095-3105, 2003.
74. Khan MM, Evans DR, Gunna V, et al.: Reduced erythrocyte membrane essential fatty acids and increased lipid peroxides in schizophrenia at the never-medicated first-episode of psychosis and after years of treatment with antipsychotics. Schizophr Res 58:1-10, 2002.
75. Knable MB, Weinberger DR: Dopamine, the prefrontal cortex and schizophrenia. J Psychopharmacol 11:123-131, 1997.
76. Koslow SH, Maas JW, Bowden CL, et al.: CSF and urinary biogenic amines and metabolites in depression and mania. A controlled, univariate analysis. Arch Gen Psychiatr 40:999-1010, 1983.
77. Kristal BS, Kaddurah-Daouk R, Beal MF, et al.: Metabolomics: Concept and potential neuroscience application, in Handbook of Neurochemistry and Molecular Neurobiology: Brain Energetics. Integration of Molecular and Cellular Processes. Edited by. Berlin Heidelberg New York, Springer, 2007, pp. 889-912.
78. Kristal BS, Shurubor YI, Kaddurah-Daouk R, et al.: Metabolomics in the study of aging and caloric restriction. Methods Mol Biol 371:393-409, 2007.
79. Kugaya A, Sanacora G: Beyond monoamines: Glutamatergic function in mood disorders. CNS Spectrum 10:808-819, 2005.
80. Lake CR, Pickar D, Ziegler MG, et al.: High plasma norepinephrine levels in patients with major affective disorder. Am J Psychiatr 139:1315-1318, 1982.
81. Lassere MN, Johnson KR, Boers M, et al.: Definitions and validation criteria for biomarkers and surrogate endpoints: Development and testing of a quantitative hierarchical levels of evidence schema. J Rheumatol 34:607-615, 2007.
82. Leonard BE: Evidence for a biochemical lesion in depression. J Clin Psychiatr 61 (Suppl. 6):12-17, 2000.
83. Leoni V, Masterman T, Patel P, et al.: Side chain oxidized oxysterols in cerebrospinal fluid and the integrity of blood-brain and blood-cerebrospinal fluid barriers. J Lipid Res 44:793-799, 2003.
84. Levine J, Panchalingam K, Rapoport A, et al.: Increased cerebrospinal fluid glutamine levels in depressed patients. Biol Psychiatr 47:586-593, 2000.
85. Levine J, Sela BA, Osher Y, et al.: High homocysteine serum levels in young male schizophrenia and bipolar patients and in an animal model. Prog Neuropsychopharmacol Biol Psychiatr 29:1181-1191, 2005.
86. Lewine RR, Risch SC, Risby E, et al.: Lateral ventricle-brain ratio and balance between CSF HVA and 5-HIAA in schizophrenia. Am J Psychiatr 148:1189-1194, 1991.
87. Lieb J, Karmali R, Horrobin D: Elevated levels of prostaglandin E2 and thromboxane B2 in depression. Prostaglandins Leukot Med 10:361-367, 1983.
88. Lieberman JA, Mailman RB, Duncan G, et al.: Serotonergic basis of antipsychotic drug effects in schizophrenia. Biol Psychiatr 44:1099-1117, 1998.
89. Lin PY, Su KP: A meta-Analytic review of double-blind, placebo-controlled trials of antidepressant efficacy of omega-3 fatty acids. J Clin Psychiatr 68:1056-1061, 2007.
90. Lindon JC, Nicholson JK, Holmes E, et al.: Metabonomics: Metabolic processes studied by NMR spectroscopy of biofluids. Concepts Magn Reson 12:289-320, 2000.
91. Lindon JC, Nicholson JK, Holmes E, et al.: Contemporary issues in toxicology the role of metabonomics in toxicology and its evaluation by the COMET project. Toxicol Appl Pharmacol 187:137-146, 2003.
92. Lindon JC, Holmes E, Nicholson JK: Metabonomics in pharmaceutical R&D. FEBS J 274:1149-1151, 2007.
93. Lucini V, Lucca A, Catalano M, et al.: Predictive value of tryptophan/large neutral amino acids ratio to antidepressant response. J Affect Disord 36:129-133, 1996.
94. Maas JW, Dekirmenjian H, Fawcett JA: MHPG excretion by patients with affective disorders. Int Pharmacopsychiatr 9:14-26, 1974.
95. Maeng S, Zarate CA, Jr., Du J, et al.: Cellular mechanisms underlying the antidepressant effects of ketamine: Role of alpha-Amino-3-hydroxy-5- methylisoxazole-4-propionic Acid Receptors. Biol Psychiatr 63:349-352, 2008.
96. Maes M, Scharpe S, Meltzer HY, et al.: Increased neopterin and interferon-gamma secretion and lower availability of L-Tryptophan in major depression: Further evidence for an immune response. Psychiatr Res 54:143-160, 1994.
97. Mahadik SP, Mukherjee S, Correnti EE, et al.: Plasma membrane phospholipid and cholesterol distribution of skin fibroblasts from drug-naive patients at the onset of psychosis. Schizophr Res 13:239-247, 1994.
98. Mahmood T, Silverstone T: Serotonin and bipolar disorder. J Affect Disord 66:1-11, 2001.
99. Maier B, Laurer HL, Rose S, et al.: Physiological levels of pro-And anti-inflammatory mediators in cerebrospinal fluid and plasma: A normative study. J Neurotrauma 22:822-835, 2005.
100. Maj M, Ariano MG, Arena F, et al.: Plasma cortisol, catecholamine and cyclic AMP levels, response to dexamethasone suppression test and platelet MAO activity in manic-depressive patients. A longitudinal study. Neuropsychobiology 11:168-173, 1984.
101. Makatsori A, Duncko R, Moncek F, et al.: Modulation of neuroendocrine response and non-verbal behavior during psychosocial stress in healthy volunteers by the glutamate release-inhibiting drug lamotrigine.
102. Makatsori A, Duncko R, Moncek F, et al.: Modulation of neuroendocrine response and non-verbal behavior during psychosocial stress in healthy volunteers by the glutamate release-inhibiting drug lamotrigine. Neuroendocrinology 79:34-42, 2004.
103. Mann JJ, Oquendo M, Underwood MD, et al.: The neurobiology of suicide risk: A review for the clinician. J Clin Psychiatr 60 (Suppl. 2):7-11; discussion 18-20, 113-116, 1999.
104. Mazure CM, Bowers MB: Pretreatment plasma HVA predicts neuroleptic response in manic psychosis. J Affect Disord 48:83-86, 1998.
105. Meisenzahl EM, Schmitt GJ, Scheuerecker J, et al.: The role of dopamine for the pathophysiology of schizophrenia. Int Rev Psychiatr 19:337-345, 2007.
106. Miyamoto S, LaMantia AS, Duncan GE, et al.: Recent advances in the neurobiology of schizophrenia. Mol Interv 3:27-39, 2003.
107. Mooney JJ, Schatzberg AF, Cole JO, et al.: Urinary 3-methoxy-4- hydroxyphenylglycol and the depression-Type score as predictors of differential responses to antidepressants. J Clin Psychopharmacol 11:339-343, 1991.
108. Morvan D, Demidem A: Metabolomics by proton nuclear magnetic resonance spectroscopy of the response to chloroethylnitrosourea reveals drug efficacy and tumor adaptive metabolic pathways. Cancer Res 67:2150-2159, 2007.
109. Mueller PS, Davis JM, Bunney WE, Jr., et al.: Plasma free fatty acids concentration in depressive illness. Arch Gen Psychiatr 22:216-221, 1970.
110. Muller N, Riedel M, Schwarz MJ: Psychotropic effects of COX-2 inhibitors-A possible new approach for the treatment of psychiatric disorders. Pharmacopsychiatry 37:266-269, 2004.
111. Muller N, Schwarz MJ, Dehning S, et al.: The cyclooxygenase-2 inhibitor celecoxib has therapeutic effects in major depression: Results of a double-blind, randomized, placebo controlled, addon pilot study to reboxetine. Mol Psychiatr 11:680-684, 2006.
112. Murakami M, Kudo I: Phospholipase A2. J Biochem (Tokyo) 131:285-292, 2002.
113. Nanda BL, Nataraju A, Rajesh R, et al.: PLA2 mediated arachidonate free radicals: PLA2 inhibition and neutralization of free radicals by anti-oxidants-A new role as anti-inflammatory molecule. Curr Top Med Chem 7:765-777, 2007.
114. Nicholson JK: Global systems biology, personalized medicine and molecular epidemiology. Mol Syst Biol 2:52, 2006.
115. Obeid R, Kostopoulos P, Knapp JP, et al.: Biomarkers of folate and vitamin B12 are related in blood and cerebrospinal fluid. Clin Chem 53:326-333, 2007.
116. Odunsi K, Wollman RM, Ambrosone CB, et al.: Detection of epithelial ovarian cancer using 1HNMR-based metabonomics. Int J Cancer 113:782-788, 2005.
117. Paige LA, Mitchell MW, Krishnan KR, et al.: A preliminary metabolomic analysis of older adults with and without depression. Int J Geriatr Psychiatr 22:418-423, 2007.
118. Palomino A, Gonzalez-Pinto A, Aldama A, et al.: Decreased levels of plasma glutamate in patients with first-episode schizophrenia and bipolar disorder. Schizophr Res 95:174-178, 2007.
119. Pani L, Pira L, Marchese G: Antipsychotic efficacy: Relationship to optimal D2-receptor occupancy. Eur Psychiatr 22:267-275, 2007.
120. Patterson AD, Li H, Eichler GS, et al.: UPLC-ESI-TOFMS-based metabolomics and gene expression dynamics inspector self-organizing metabolomic maps as tools for understanding the cellular response to ionizing radiation. Anal Chem 80:665-674, 2008.
121. Peet M, Moody JP, Worrall EP, et al.: Plasma tryptophan concentration in depressive illness and mania. Br J Psychiatr 128:255-258, 1976.
122. Petty F, Schlesser MA: Plasma GABA in affective illness. A preliminary investigation. J Affect Disord 3:339-343, 1981.
123. Petty F, Rush AJ, Davis JM, et al.: Plasma GABA predicts acute response to divalproex in mania. Biol Psychiatr 39:278-284, 1996.
124. Piccirillo G, Fimognari FL, Infantino V, et al.: High plasma concentrations of cortisol and thromboxane B2 in patients with depression. Am J Med Sci 307:228-232, 1994.
125. Portilla D, Li S, Nagothu KK, et al.: Metabolomic study of cisplatin-induced nephrotoxicity. Kidney Int 69:2194-2204, 2006.
126. Rapoport SI, Bosetti F: Do lithium and anticonvulsants target the brain arachidonic acid cascade in bipolar disorder? Arch Gen Psychiatr 59:592-596, 2002.
127. Reddy R, Keshavan M, Yao JK: Reduced plasma antioxidants in first-episode patients with schizophrenia. Schizophr Res 62:205-212, 2003.
128. Ross BM, Seguin J, Sieswerda LE: Omega-3 fatty acids as treatments for mental illness: Which disorder and which fatty acid? Lipids Health Dis 6:21, 2007.
129. Roy A, Guthrie S, Pickar D, et al.: Plasma norepinephrine responses to cold challenge in depressed patients and normal controls. Psychiatr Res 21:161-168, 1987.
130. Roy A: Plasma HVA levels in depressed patients and controls. J Affect Disord 14:293-296, 1988.
131. Rozen S, Cudkowicz ME, Bogdanov M, et al.: Metabolomic analysis and signatures in motor neuron disease. Metabolomics 1:101-108, 2005.
132. Sabatine MS, Liu E, Morrow DA, et al.: Metabolomic identification of novel biomarkers of myocardial ischemia. Circulation 112:3868-3875, 2005.
133. Sajda P: Machine learning for detection and diagnosis of disease. Annu Rev Biomed Eng 8:537-565, 2006.
134. Sanacora G, Saricicek A: GABAergic contributions to the pathophysiology of depression and the mechanism of antidepressant action. CNS Neurol Disord Drug Targets 6:127-140, 2007.
135. Schatzberg AF, Orsulak PJ, Rosenbaum AH, et al.: Catecholamine measures for diagnosis and treatment of patients with depressive disorders. J Clin Psychiatr 41:35-39, 1980.
136. Schatzberg AF, Orsulak PJ, Rosenbaum AH, et al.: Toward a biochemical classification of depressive disorders, V: Heterogeneity of unipolar depressions. Am J Psychiatr 139:471-475, 1982.
137. Schildkraut JJ: Biogenic amines and affective disorders. Annu Rev Med 25:333-348, 1974.
138. Schmitt A, Maras A, Petroianu G, et al.: Effects of antipsychotic treatment on membrane phospholipid metabolism in schizophrenia. J Neural Transm 108:1081-1091, 2001.
139. Segal M, Avital A, Drobot M, et al.: Serum creatine kinase level in unmedicated nonpsychotic, psychotic, bipolar and schizoaffective depressed patients. Eur Neuropsychopharmacol 17:194-198, 2007.
140. Segal M, Avital A, Drobot M, et al.: CK levels in unmedicated bipolar patients. Eur Neuropsychopharmacol 17:763-767, 2007.
141. Sher L, Carballo JJ, Grunebaum MF, et al.: A prospective study of the association of cerebrospinal fluid monoamine metabolite levels with lethality of suicide attempts in patients with bipolar disorder. Bipolar Disord 8:543-550, 2006.
142. Shin H, Markey MK: A machine learning perspective on the development of clinical decision support systems utilizing mass spectra of blood samples. J Biomed Inform 39:227-248, 2006.
143. Sicras-Mainar A, Blanca-Tamayo M, Rejas-Gutierrez J, et al.: Metabolic syndrome in outpatients receiving antipsychotic therapy in routine clinical practice: A cross-sectional assessment of a primary health care database. Eur Psychiatr 23:100-108, 2008.
144. Skosnik PD, Yao JK: From membrane phospholipid defects to altered neurotransmission: Is arachidonic acid a nexus in the pathophysiology of schizophrenia? Prostaglandins Leukot Essent Fatty Acids 69:367-384, 2003.
145. Sobczak S, Honig A, van Duinen MA, et al.: Serotonergic dysregulation in bipolar disorders: A literature review of serotonergic challenge studies. Bipolar Disord 4:347-356, 2002.
146. Steuer R, Morgenthal K, Weckwerth W, et al.: A gentle guide to the analysis of metabolomic data. Methods Mol Biol 358:105-126, 2007.
147. Sublette ME, Russ MJ, Smith GS: Evidence for a role of the arachidonic acid cascade in affective disorders: A review. Bipolar Disord 6:95-105, 2004.
148. Swann AC, Secunda S, Davis JM, et al.: CSF monoamine metabolites in mania. Am J Psychiatr 140:396-400, 1983.
149. Swann AC, Petty F, Bowden CL, et al.: Mania: Gender, transmitter function, and response to treatment. Psychiatr Res 88:55-61, 1999.
150. Tandon R, Channabasavanna SM, Greden JF: CSF biochemical correlates of mixed affective states. Acta Psychiatr Scand 78:289-297, 1988.
151. Taylor V, MacQueen G: Associations between bipolar disorder and metabolic syndrome: A review. J Clin Psychiatr 67:1034-1041, 2006.
152. Tkachev D, Mimmack ML, Huffaker SJ, et al.: Further evidence for altered myelin biosynthesis and glutamatergic dysfunction in schizophrenia. Int J Neuropsychopharmacol 10:557-563, 2007.
153. Tsang TM, Huang JT, Holmes E, et al.: Metabolic profiling of plasma from discordant schizophrenia twins: Correlation between lipid signals and global functioning in female schizophrenia patients. J Proteome Res 5:756-760, 2006.
154. Underwood B, Broadhurst D, Dunn WB, et al.: Huntington disease patients and transgenic mice have similar pro-catabolic serum metabolite profiles. Brain 129:877-886, 2006.
155. van der Greef J, Martin S, Juhasz P, et al.: The art and practice of systems biology in medicine: Mapping patterns of relationships. J Proteome Res 6:1540-1559, 2007.
156. van Doorn M, Vogels J, Tas A, et al.: Evaluation of metabolite profiles as biomarkers for the pharmacological effects of thiazolidinediones in Type 2 diabetes mellitus patients and healthy volunteers. Br J Clin Pharmacol 63:562-574, 2007.
157. Vasan RS: Biomarkers of cardiovascular disease: Molecular basis and practical considerations. Circulation 113:2335-2362, 2006.
158. Wang C, Kong H, Guan Y, et al.: Plasma phospholipid metabolic profiling and biomarkers of type 2 diabetes mellitus based on high-performance liquid chromatography/electrospray mass spectrometry and multivariate statistical analysis. Anal Chem 77:4108-4116, 2005.
159. Watkins SM, Reifsnyder PR, Pan HJ, et al.: Lipid metabolome-wide effects of the PPARgamma agonist rosiglitazone. J Lipid Res 43:1809-1811, 2002.
160. Watkins SM: Lipomic profiling in drug discovery, development and clinical trial evaluation. Curr Opin Drug Discov Devel 7:112-117, 2004.
161. Watson AD: Thematic review series: Systems biology approaches to metabolic and cardiovascular disorders. Lipidomics: A global approach to lipid analysis in biological systems. J Lipid Res 47:2101-2111, 2006.
162. Weljie AM, Dowlatabadi R, Miller BJ, et al.: An inflammatory arthritis-Associated metabolite biomarker pattern revealed by 1H NMR spectroscopy. J Proteome Res 6:3456-3464, 2007.
163. Wichers MC, Koek GH, Robaeys G, et al.: IDO and interferon-Alpha-induced depressive symptoms: A shift in hypothesis from tryptophan depletion to neurotoxicity. Mol Psychiatr 10:538-544, 2005.
164. Wiest MM, Watkins SM: Biomarker discovery using high-dimensional lipid analysis. Curr Opin Lipidol 18:181-186, 2007.
165. Wong DF, Wagner HN, Jr., Tune LE, et al.: Positron emission tomography reveals elevated D2 dopamine receptors in drug-naive schizophrenics Science 234:1558-1563, 1986.
166. Yang J, Xu G, Zheng Y, et al.: Diagnosis of liver cancer using HPLC-based metabonomics avoiding false-positive result from hepatitis and hepatocirrhosis diseases. J Chromatogr B Analyt Technol Biomed Life Sci 813:59-65, 2004.
167. Yao JK, Reddy R, McElhinny LG, et al.: Reduced status of plasma total antioxidant capacity in schizophrenia. Schizophr Res 32:1-8, 1998.
168. Yao JK, Reddy R, van Kammen DP: Reduced level of plasma antioxidant uric acid in schizophrenia. Psychiatr Res 80:29-39, 1998.
169. Yao JK, Reddy RD, van Kammen DP: Human plasma glutathione peroxidase and symptom severity in schizophrenia. Biol Psychiatr 45:1512-1515, 1999.
170. Yao JK, Reddy R, van Kammen DP: Abnormal age-related changes of plasma antioxidant proteins in schizophrenia. Psychiatr Res 97:137-151, 2000.
171. Yao JK, Reddy RD, van Kammen DP: Oxidative damage and schizophrenia: An overview of the evidence and its therapeutic implications. CNS Drugs 15:287-310, 2001.
172. Yao JK, Thomas EA, Reddy RD, et al.: Association of plasma apolipoproteins D with RBC membrane arachidonic acid levels in schizophrenia. Schizophr Res 72:259-266, 2005.
173. Yao JK, Leonard S, Reddy R: Altered glutathione redox state in schizophrenia. Dis Markers 22:83-93, 2006.
174. Yoshimura R, Nakano Y, Hori H, et al.: Effect of risperidone on plasma catecholamine metabolites and brain-derived neurotrophic factor in patients with bipolar disorders. Hum Psychopharmacol 21:433-438, 2006.
175. Young LT, Warsh JJ, Kish SJ, et al.: Reduced brain 5-HT and elevated NE turnover and metabolites in bipolar affective disorder. Biol Psychiatr 35:121-127, 1994.
176. Yuan K, Kong H, Guan Y, et al.: A GC-based metabonomics investigation of type 2 diabetes by organic acids metabolic profile. J Chromatogr B Analyt Technol Biomed Life Sci 850:236-240, 2007.
177. Yumru M, Savas HA, Kurt E, et al.: Atypical antipsychotics related metabolic syndrome in bipolar patients. J Affect Disord 98:247-252, 2007.
178. Zarate CA, Jr., Singh JB, Carlson PJ, et al.: A randomized trial of an N-methyl-D-Aspartate antagonist in treatment-resistant major depression. Arch Gen Psychiatr 63:856-864, 2006.